Doctors prescribing drugs like Ozempic have gotten very good at anticipating outcomes.
It’s easy to anticipate that blood sugar will likely come down, and weight will probably drop.
What’s proved much harder to predict is why some patients see dramatic results after a year on the medication, while others on the same drug and same dose see far less.
A year-long study from Japan suggests the explanation isn’t in the drug at all – it’s in how the patient overeats.
A puzzle that’s hard to explain
Ozempic, Wegovy, and Mounjaro have transformed care for many people with type 2 diabetes.
But the results are uneven. Some patients lose 20 pounds and watch their numbers stabilize. Others see only modest changes after a year on the same medication.
A team led by Professor Daisuke Yabe of Kyoto University and Dr. Takehiro Kato of Gifu University followed 92 adults with type 2 diabetes through their first 12 months on these drugs.
Working across hospitals in Gifu Prefecture, Japan, they wanted to know whether the way a person tends to overeat could predict who would benefit most.
Drugs change eating behavior
GLP-1 drugs mimic a hormone the gut releases after meals. They prompt the pancreas to release more insulin and slow how fast the stomach empties.
They also appear to reduce appetite through signals in the brain – though exactly how much weight any one person loses from that effect varies considerably.
Appetite runs on different inputs: the sight of food, the smell of food, the pull of stress or sadness. A drug that quiets one input may leave the others largely untouched.
Three differing eating patterns
A validated questionnaire sorted participants by how they tend to overeat. Three patterns emerged.
The first was external eating – reaching for food because it looks or smells good, even when not hungry.
The second was emotional eating – eating to cope with stress, sadness, or boredom. Restrained eating, the third pattern, involved the deliberate effort to limit intake.
Most people show some mix of all three. The question was whether that mix changed how well the drug worked over a full year.
A full year of tracking
Participants started one of four GLP-1 medications – oral or injectable semaglutide, dulaglutide, or liraglutide.
Researchers tracked weight, body fat, blood sugar, cholesterol, and dietary intake at the start, at three months, and at 12 months.
By year’s end, the average participant had lost about 8 pounds and dropped nearly 2 percentage points of body fat.
Blood sugar came down from an HbA1c of 8.2 to 7.0 – HbA1c being a standard measure of average blood sugar control over several months.
Muscle mass held steady throughout – an unusual finding given recurring concerns about muscle loss on these drugs – and cholesterol numbers improved as well.
External eating stands out
At the three-month checkup, all three eating-behavior scores were moving. Emotional eating dropped. Restrained eating ticked up. External eating fell.
Then the patterns diverged. Emotional eating drifted back to baseline by month 12. Restrained eating did the same.
But external eating stayed lower for the full year – against the direction of an earlier report.
Until this study, no one had clearly shown which eating pattern best predicts long-term success on GLP-1 drugs in real clinical practice.
Higher external eating scores at the start of treatment predicted greater weight loss after 12 months.
The stronger a person’s pull toward tempting food at the outset, the more weight they tended to lose. Emotional eating showed no such link.
Connection of brain cues and appetite
What might explain it? Brain imaging offers a clue. People with higher body mass often show heightened activity in brain areas linked to craving and reward when shown pictures of food.
A trial using a related GLP-1 drug found that this elevated activity appeared to ease during treatment.
Whether the drug produces this effect directly, or works through other appetite pathways, isn’t fully settled.
The behavioral pattern is clear either way. External eaters reported less pull toward tempting food, and that change held across 12 months.
Treatment may need tailoring
“GLP-1 receptor agonists are effective for individuals who experience weight gain or elevated blood glucose levels due to overeating triggered by external stimuli.” said Yabe.
“However, their effectiveness is less expected in cases where emotional eating is the primary cause,” he continued.
A separate study showed emotional eaters experience less change in food-cue brain activity on GLP-1 therapy, mirroring this paper’s year-long pattern.
Ask a patient why they tend to overeat, and the answer starts to look like a clinical signal.
Limitations worth noting
The 92-person study was observational and relied partly on self-reported eating behavior, which limits how firmly causes can be established.
Participants came from a single region of Japan, and many appeared highly motivated to improve their health.
This profile that may not reflect the broader population of people starting these medications.
Important clinical implications
Now there’s a clearer answer to why GLP-1 drugs work unevenly. External eating is described as the pull toward food that looks or smells appealing.
This turned out to be the sharpest predictor of long-term success on these medications.
The clinical question changes accordingly. It’s no longer simply whether to prescribe Ozempic, but whether to pair it with something more.
For people who eat because food looks irresistible, the drug carries the load. For people who eat because they are hurting, it’s one piece of a bigger answer.
The study is published in the journal Frontiers in Clinical Diabetes and Healthcare.
—–
Like what you read? Subscribe to our newsletter for engaging articles, exclusive content, and the latest updates.
Check us out on EarthSnap, a free app brought to you by Eric Ralls and Earth.com.
—–